Skip links

Atropine & Myopia Control

Low Dose Atropine & Myopia Control

Atropine has been researched as a treatment for myopia control since the 1900s. A compelling body of literature from well-designed studies have corroborated the role of low-dose atropine in myopia control.

One of the landmark studies, such as the Atropine for the Treatment of Myopia (ATOM 1) found that higher concentrations of atropine (0.5% and 1%) could slow down myopia progression (in terms of both axial length and refractive error). In 2012, the results from the Atropine for the Treatment of Myopia 2 ( ATOM 2) study indicated that the lower concentration of atropine (0.01%) applied daily produced similar levels of reduction in the rates of refractive error progression as 0.5% and 0.1%, and had minimal side effects. However, 0.01% did not produce a significant impact on slowing down eye elongation, which is responsible for myopia related pathologies. In addition, rebound effect was more pronounced in children that received higher concentration of atropine (1.0%, 0.5%, 0.1%) in comparison to 0.01% and it become a common choice of treatment among eyecare professionals.

Latest updates

“Efficacy of 0.05% atropine was double that observed with 0.01% .”

In 2019, the Low-Concentration Atropine for Myopia Progression (LAMP) study released its results from its first phase. This randomized, double-masked, placebo controlled study confirmed the efficacy of low-concentration atropine at 0.05%, 0.025%, and 0.01% with a concentration-dependent response. Patients in the study tolerated all the concentrations without adverse effect on their vision. It was noted, that of all the concentrations used, 0.05% atropine was most effective in controlling prescription and axial length elongation over the course of one year. Over the course of 2 years, the efficacy of 0.05% atropine was double that observed with 0.01% atropine and remains the optimal concentration for slowing myopia progression.